why choose us

First received: August 17, 2022

Clinical Trial: TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent ALK Positive Large B-Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRP?-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRP?-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell

Brief Summary: This phase II trial tests the safety, side effects, and best dose of TTI-621 or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-Cell lymphoma that has come back (relapsed).TTI-621 and TTI-622 are called fusion proteins.A fusion protein includes two specialized proteins that are joined together.In TTI-621 and TTI-622, one of the proteins binds with other proteins found on the surface of certain cells that are part of the immune system.The other protein targets and blocks a…

Read more